SELTA Composition for Immune Modulation in CPPS and Arthritis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for chronic pelvic pain syndrome (CPPS) and other immune- and inflammation-related conditions are inadequate due to a lack of understanding of the complex etiology, particularly in modulating the immune response and reducing tactile allodynia.

Innovation Solution

Compositions comprising Staphylococcus epidermidis lipotechoic acid (SELTA) are administered to modulate the immune response by increasing expression of CTLA-4-like ligands PDL1 and PDL2, enhancing IL10 secretion, and increasing CD4 CD25 FoxP3+ T-regulatory cells, thereby reducing tactile allodynia and inflammation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments are used for CPPS and immune-related conditions, then current standard care is provided, but the immune response cannot be effectively modulated and tactile allodynia persists

Engineering Contradiction:

Improveimmune response modulationVSAvoidtactile allodynia

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the molecular parameters of the treatment by using specifically engineered lipoteichoic acid compositions with defined chemical structures (Formula I) containing specific fatty acid chains and sugar moieties. This molecular parameter change enables effective modulation of immune response and reduction of tactile allodynia that conventional treatments cannot achieve.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The lipoteichoic acid acts as an intermediary substance that mediates between the immune system and the pathogenic stimuli. It specifically interacts with TLR2 receptors to modulate immune signaling pathways, thereby reducing tactile allodynia and inflammation without directly eliminating the underlying cause of the disease.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If the etiology of CPPS is fully understood and targeted treatments are developed, then effective immune modulation is achieved, but the complexity of the disease mechanism increases the difficulty of treatment development

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidtreatment development complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent extracts the essential therapeutic activity from the complex bacterial cell wall structure by isolating and purifying the lipoteichoic acid component. This extraction allows the treatment to target specific immune pathways (TLR2 signaling) without the complexity of delivering entire bacterial organisms or complex microbial communities, thereby simplifying treatment development while maintaining effectiveness.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The treatment approach segments the complex immune modulation process into specific targetable components: identifying particular TLR2 signaling pathways, isolating specific lipoteichoic acid molecules with defined structures, and delivering purified compositions that act on specific immune cells (dendritic cells, macrophages). This segmentation reduces the complexity of treating the overall disease by focusing on discrete molecular targets.

Inventive Principle:

Principle #1Segmentation

3Quantity of substance

If broad-spectrum antimicrobials are used to clear bacteria, then infection is reduced, but the complex immune activation and inflammation persist

Engineering Contradiction:

Improvebacterial clearanceVSAvoidinflammation

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The patent converts the harmful effect of bacterial cell wall components (which trigger inflammation) into a beneficial therapeutic mechanism. The lipoteichoic acid, normally a pathogen-associated molecular pattern that causes inflammation, is used in a purified, controlled form to specifically modulate TLR2 signaling and reduce unwanted immune activation. This transforms the harmful inflammatory trigger into a therapeutic immune modulator.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

SELTA effectively reverses tactile allodynia and inflammation by specifically modulating the immune response, demonstrating strain-specific effects in murine models of CPPS and arthritis.

Implementation Method 1

Methodology Applied

Scientific EffectImmune modulation:

Implementation Method 2

SELTA effectively reverses tactile allodynia and inflammation by specifically modulating the immune response

Methodology Applied

Scientific EffectAnti-inflammatory effect:

Data Source

PatentUS20260014181A1Lipotechoic acid for immune modulation

Publication Date: 2026.01.15 NORTHWESTERN UNIV

AI summary

Provided herein are compositions comprising lipotechoic acid (LTA) and methods of use thereof for immune modulation. In particular, compositions comprising S. epidermidis lipotechoic Acid (SELTA) are provided, as well as method of use thereof for the treatment of immune—(e.g., autoimmune) and inflammation-related conditions and diseases (e.g., chronic pelvic pain syndrome (CPPS), arthritis, etc.).